Dr. Reddy's Laboratories Limited

Informe acción NSEI:DRREDDY

Capitalización de mercado: ₹993.4b

Dr. Reddy's Laboratories Dirección

Dirección controles de criterios 2/4

El CEO de Dr. Reddy's Laboratories es Erez Israeli, nombrado en Apr 2018, tiene una permanencia de 6.58 años. posee directamente un 0.007% de las acciones de la empresa, con un valor de ₹65.07M. La antigüedad media del equipo directivo y de la junta directiva es de 6.6 años y 2.8 años, respectivamente.

Información clave

Erez Israeli

Chief Executive Officer (CEO)

₹197.1m

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO6.6yrs
Participación del CEO0.007%
Permanencia media de la dirección6.6yrs
Promedio de permanencia en la Junta Directiva2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?

Nov 23
Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?

Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next

Nov 08
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next

Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price

Nov 01
Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price

Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

Oct 14
Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Aug 19
If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Aug 01
Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet

Jul 30
The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet

Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly

Jul 12
Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly

Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00

Jun 23
Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00

Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings

Jun 20
Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00

May 26
Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00

Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00

May 10
Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00

With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case

May 06
With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case

There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding

Apr 18
There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding

Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 02
Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?

Jan 19
Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?

Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E

Jan 01
Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E

Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet

Oct 21
Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Oct 03
If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt

Jul 14
Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

Jun 24
Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year

Jun 10
Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

May 27
Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00

May 13
Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00

Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

Apr 11
Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Mar 06
If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well

Jan 10
These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dec 05
If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Erez Israeli en comparación con los beneficios de Dr. Reddy's Laboratories?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

₹53b

Jun 30 2024n/an/a

₹56b

Mar 31 2024₹197mn/a

₹56b

Dec 31 2023n/an/a

₹52b

Sep 30 2023n/an/a

₹51b

Jun 30 2023n/an/a

₹47b

Mar 31 2023₹195mn/a

₹45b

Dec 31 2022n/an/a

₹36b

Sep 30 2022n/an/a

₹31b

Jun 30 2022n/an/a

₹30b

Mar 31 2022₹127mn/a

₹24b

Dec 31 2021n/an/a

₹26b

Sep 30 2021n/an/a

₹19b

Jun 30 2021n/an/a

₹17b

Mar 31 2021₹120mn/a

₹17b

Dec 31 2020n/an/a

₹21b

Sep 30 2020n/an/a

₹15b

Jun 30 2020n/an/a

₹19b

Mar 31 2020₹195m₹107m

₹19b

Dec 31 2019n/an/a

₹16b

Sep 30 2019n/an/a

₹27b

Jun 30 2019n/an/a

₹21b

Mar 31 2019₹123mn/a

₹19b

Compensación vs. Mercado: La compensación total de Erez($USD2.33M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD1.08M).

Compensación vs. Ingresos: La compensación de Erez ha sido consistente con los resultados de la empresa en el último año.


CEO

Erez Israeli (56 yo)

6.6yrs

Permanencia

₹197,090,000

Compensación

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Gunupati Prasad
Co-Chairman38.6yrs₹186.28m13.07%
₹ 129.9b
Kallam Reddy
Chairman of the Board & Member of the Management Council31.8yrs₹116.17m13.61%
₹ 135.2b
Erez Israeli
CEO & Member of the Management Council6.6yrs₹197.09m0.0066%
₹ 65.1m
Mannam Venkatanarasimham
CFO & Member of the Management Councilless than a year₹48.82m0.0057%
₹ 56.3m
Krishna Venkatesh
Global Head of Quality and Pharmacovigilance & Member of the Management Councilless than a year₹6.15msin datos
Deepak Sapra
CEO of API & Services & Member of Management Councilno data₹41.90m0.0027%
₹ 26.6m
Venkata Motupalli
CEO of Branded Markets - India & Emerging Countries and Member of Management Councilno data₹82.74m0.016%
₹ 156.3m
Archana Bhaskar
EVP, Head of Corporate Communications7.4yrs₹65.21m0.0063%
₹ 63.1m
Sanjay Sharma
Executive VP7.3yrs₹66.05msin datos
Patrick Aghanian
CEO of European Generics & Member of Management Councilno data₹63.09msin datos
Sushrut Kulkarni
Global Head of Integrated Product Development Organisation & Member of the Management Councilno data₹55.63m0.000020%
₹ 198.7k
Jayanth Sridhar
Global Head – Biologics & Member of the Management Councilno data₹34.59msin datos

6.6yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DRREDDY es experimentado (6.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Gunupati Prasad
Co-Chairman38.6yrs₹186.28m13.07%
₹ 129.9b
Kallam Reddy
Chairman of the Board & Member of the Management Council31.8yrs₹116.17m13.61%
₹ 135.2b
R. Rajgopalan
Member of the Scientific Advisory Boardno data₹8.36msin datos
Arun Kumar
Independent Director2.3yrs₹18.77msin datos
Shikha Sharma
Independent Director5.8yrs₹13.34msin datos
K. Reddy
Member of the Scientific Advisory Boardno datasin datossin datos
Leo Puri
Lead Independent Director6.1yrs₹17.10msin datos
Kodumudi Krishnan
Independent Director2.8yrs₹14.18msin datos
Sanjiv Mehta
Independent Directorless than a year₹3.32msin datos
Alpna Seth
Independent Director1.8yrs₹8.25msin datos
Penny Wan
Independent Director2.8yrs₹17.10msin datos
Claudio Albrecht
Independent Director1.5yrs₹16.09msin datos

2.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de DRREDDY no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.